149 related articles for article (PubMed ID: 36759266)
1. Rationale and Design of a Single-Arm, Phase 2, Multi-Center Study of Chemo-Immunotherapy Followed by Hypo-Fractionated RT and Maintenance Immunotherapy in Patients With Unresectable Stage III NSCLC: The DEDALUS Trial.
Filippi AR; Agustoni F; Arcangeli S; Cortinovis D; Ferrari A; Cicognini D; Saddi J; Klersy C; Pedrazzoli P; Malapelle U; Grossi F
Clin Lung Cancer; 2023 May; 24(3):e122-e125. PubMed ID: 36759266
[TBL] [Abstract][Full Text] [Related]
2. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
[TBL] [Abstract][Full Text] [Related]
3. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
Kaira K; Mouri A; Kato S; Yoshimura K; Kagamu H; Kobayashi K
BMC Cancer; 2020 Oct; 20(1):961. PubMed ID: 33023530
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study).
Yamada T; Uchino J; Chihara Y; Shimamoto T; Iwasaku M; Tamiya N; Kaneko Y; Kiyomi F; Takayama K
Ther Adv Med Oncol; 2020; 12():1758835920927841. PubMed ID: 32536981
[TBL] [Abstract][Full Text] [Related]
6. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.
Bruni A; Scotti V; Borghetti P; Vagge S; Cozzi S; D'Angelo E; Giaj Levra N; Fozza A; Taraborrelli M; Piperno G; Vanoni V; Sepulcri M; Trovò M; Nardone V; Lattanzi E; Bou Selman S; Bertolini F; Franceschini D; Agustoni F; Jereczek-Fossa BA; Magrini SM; Livi L; Lohr F; Filippi AR
Front Oncol; 2021; 11():744956. PubMed ID: 34650927
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
8. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
[TBL] [Abstract][Full Text] [Related]
9. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
Faivre-Finn C; Spigel DR; Senan S; Langer C; Perez BA; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Hui R; Murakami S; Paz-Ares L; Broadhurst H; Wadsworth C; Dennis PA; Antonia SJ
Lung Cancer; 2021 Jan; 151():30-38. PubMed ID: 33285469
[TBL] [Abstract][Full Text] [Related]
10. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
11. Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Merlotti A; Bruni A; Borghetti P; Ramella S; Scotti V; Trovò M; Chiari R; Lohr F; Ricardi U; Bria E; Pappagallo GL; D'Angelillo RM; Arcangeli S
Radiol Med; 2021 Aug; 126(8):1117-1128. PubMed ID: 33954898
[TBL] [Abstract][Full Text] [Related]
12. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
Clin Lung Cancer; 2022 May; 23(3):e264-e268. PubMed ID: 34489161
[TBL] [Abstract][Full Text] [Related]
13. Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience.
Borghetti P; Volpi G; Facheris G; Cossali G; Mataj E; La Mattina S; Singh N; Imbrescia J; Bonù ML; Tomasini D; Vitali P; Greco D; Bezzi M; Melotti F; Benvenuti M; Borghesi A; Grisanti S; Buglione di Monale E Bastia M
Front Oncol; 2023; 13():1208204. PubMed ID: 37469420
[TBL] [Abstract][Full Text] [Related]
14. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
[TBL] [Abstract][Full Text] [Related]
15. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy.
Zhou Q; Chen M; Wu G; Chang JH; Jiang O; Cui JW; Han G; Lin Q; Fang J; Chen GY; Wu YL
Transl Lung Cancer Res; 2020 Oct; 9(5):2008-2015. PubMed ID: 33209620
[TBL] [Abstract][Full Text] [Related]
16. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
Senan S; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Murakami S; Hui R; Faivre-Finn C; Paz-Ares L; Wu YL; Mann H; Dennis PA; Antonia SJ
ESMO Open; 2022 Apr; 7(2):100410. PubMed ID: 35247871
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience.
Vrankar M; Stanic K; Jelercic S; Ciric E; Vodusek AL; But-Hadzic J
Radiol Oncol; 2021 Nov; 55(4):482-490. PubMed ID: 34821136
[TBL] [Abstract][Full Text] [Related]
18. Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era.
Catania C; Piperno G; Russo A; Greco C; Agustoni F; Scotti V; Proto C; Sangalli C; Patani F; Santacaterina A; Di Pietro Paolo M; Agresti B; Filippi AR; Ramella S
Crit Rev Oncol Hematol; 2022 Jun; 174():103684. PubMed ID: 35462031
[TBL] [Abstract][Full Text] [Related]
19. Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
Kuon J; Hommertgen A; Krisam J; Lasitschka F; Stenzinger A; Blasi M; Bozorgmehr F; Maenz M; Kieser M; Schneider M; Thomas M
Trials; 2020 Apr; 21(1):352. PubMed ID: 32321565
[TBL] [Abstract][Full Text] [Related]
20. Induction Immunotherapy Followed by Thoracic Radiation without Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Case Series.
Dasari S; Komiya T
Asian Pac J Cancer Prev; 2022 Jan; 23(1):217-220. PubMed ID: 35092391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
